CytoLyt Fixation Significantly Inhibits MIB1 Immunoreactivity Whereas Alternative Ki-67 Clone 30-9 is Not Susceptible to the Inhibition: Critical Diagnostic Implications

Overview

Journal Cancer Cytopathol

Specialty Oncology

Date 2019 Aug 10

PMID 31398281

Citations 6

Authors

Darren J Buonocore

Fumiko Konno

Achim A Jungbluth

Denise Frosina

Mariam Fayad

Marcia Edelweiss

Oscar Lin

Natasha Rekhtman

Affiliations

Soon will be listed here.

Abstract

Background: The Ki-67 proliferation marker has multiple diagnostic and prognostic applications. Although several clones to the Ki-67 antigen are commercially available, the MIB1 clone is widely recommended in the surgical pathology literature for neuroendocrine tumors. In our cytopathology practice, we have encountered unexpectedly low MIB1 immunoreactivity in CytoLyt-fixed cell blocks (CBs). The current study evaluated the impact of fixatives, CB processing, and immunocytochemical (ICC) procedures on Ki-67 immunoreactivity.

Methods: Test CBs were prepared from freshly resected tumors, and multiple variables in the MIB1 ICC procedure were tested, including CytoLyt versus formalin collection media, MIB1 versus other Ki-67 clones including 30-9, and other variables. MIB1 versus Ki-67 30-9 clones were tested in parallel on CytoLyt-fixed CBs from clinical samples of small cell lung carcinoma (SCLC).

Results: In the test CBs (n = 10), the mean MIB1 labeling index was 10% in CytoLyt versus 47% in formalin (P = .0116), with a mean loss of reactivity in matched CBs of 37% (up to 70%). None of the procedure modifications tested in 223 individual ICC reactions recovered MIB1 reactivity in CytoLyt except for switching to the Ki-67 30-9 antibody. In CytoLyt-fixed SCLC samples (n = 14), the Ki-67 30-9 antibody demonstrated expected ranges of reactivity (mean, 83%; range, 60%-100%), whereas MIB1 demonstrated markedly inhibited labeling (mean, 60%; range, 10%-95%) (P = .0058).

Conclusions: CytoLyt fixation substantially inhibits MIB1 immunoreactivity, whereas the Ki-67 30-9 clone is not susceptible to inhibition. Markedly discrepant MIB1 reactivity may present a pitfall in the diagnosis of SCLC and may lead to the incorrect prognostic stratification of other tumor types. For laboratories using CytoLyt, we recommend using the Ki-67 30-9 antibody rather than the MIB1 antibody.

Citing Articles

Discrepancy of Hans' criteria for clonally related nodal and pericardiac fluid diffuse large B-cell lymphoma with MYD88 L265P mutation.

Terao T, Sato Y, Kuroda Y, Haratake T, Nishimura M, Sato Y J Clin Exp Hematop. 2024; 64(4):318-322.

PMID: 39603634 PMC: 11786154. DOI: 10.3960/jslrt.24050.

Reliability of assessing morphologic features with prognostic significance in cytology specimens of epithelioid diffuse pleural mesothelioma and implications for cytopathology reporting.

Li Y, Salama A, Baine M, Bodd F, Offin M, Rekhtman N Cancer Cytopathol. 2023; 131(8):495-506.

PMID: 37127928 PMC: 11037265. DOI: 10.1002/cncy.22705.

Nationwide differences in cytology fixation and processing methods and their impact on interlaboratory variation in PD-L1 positivity.

Koomen B, de Boer M, van Dooijeweert C, van Lindert A, Deckers I, Voorham Q Virchows Arch. 2022; 482(4):707-720.

PMID: 36370167 PMC: 10067664. DOI: 10.1007/s00428-022-03446-w.

Lung neuroendocrine neoplasms: recent progress and persistent challenges.

Rekhtman N Mod Pathol. 2021; 35(Suppl 1):36-50.

PMID: 34663914 PMC: 8695375. DOI: 10.1038/s41379-021-00943-2.

False-negative programmed death-ligand 1 immunostaining in ethanol-fixed endobronchial ultrasound-guided transbronchial needle aspiration specimens of non-small-cell lung cancer patients.

Koomen B, Vreuls W, de Boer M, de Ruiter E, Hoelters J, Vink A Histopathology. 2021; 79(4):480-490.

PMID: 33772818 PMC: 8519150. DOI: 10.1111/his.14373.

References

Klimstra D, Modlin I, Coppola D, Lloyd R, Suster S . The pathologic classification of neuroendocrine tumors: a review of nomenclature, grading, and staging systems. Pancreas. 2010; 39(6):707-12. DOI: 10.1097/MPA.0b013e3181ec124e. View

Matsumoto A, Jinno H, Ando T, Fujii T, Nakamura T, Saito J . Biological markers of invasive breast cancer. Jpn J Clin Oncol. 2015; 46(2):99-105. DOI: 10.1093/jjco/hyv153. View

Volante M, Gatti G, Papotti M . Classification of lung neuroendocrine tumors: lights and shadows. Endocrine. 2015; 50(2):315-9. DOI: 10.1007/s12020-015-0578-x. View

Rindi G, Klimstra D, Abedi-Ardekani B, Asa S, Bosman F, Brambilla E . A common classification framework for neuroendocrine neoplasms: an International Agency for Research on Cancer (IARC) and World Health Organization (WHO) expert consensus proposal. Mod Pathol. 2018; 31(12):1770-1786. PMC: 6265262. DOI: 10.1038/s41379-018-0110-y. View

Sauter J, Ambaye A, Mount S . Increased utilization, verification, and clinical implications of immunocytochemistry: Experience in a northern New England hospital. Diagn Cytopathol. 2015; 43(9):688-95. DOI: 10.1002/dc.23279. View

Pathmanathan N, Balleine R . Ki67 and proliferation in breast cancer. J Clin Pathol. 2013; 66(6):512-6. DOI: 10.1136/jclinpath-2012-201085. View

Hanley K, Birdsong G, Cohen C, Siddiqui M . Immunohistochemical detection of estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 expression in breast carcinomas: comparison on cell block, needle-core, and tissue block preparations. Cancer. 2009; 117(4):279-88. DOI: 10.1002/cncy.20034. View

Vose J . Mantle cell lymphoma: 2015 update on diagnosis, risk-stratification, and clinical management. Am J Hematol. 2015; 90(8):739-45. DOI: 10.1002/ajh.24094. View

Li L, Jiang G, Chen Q, Zheng J . Ki67 is a promising molecular target in the diagnosis of cancer (review). Mol Med Rep. 2014; 11(3):1566-72. DOI: 10.3892/mmr.2014.2914. View

10.

Crapanzano J, Heymann J, Monaco S, Nassar A, Saqi A . The state of cell block variation and satisfaction in the era of molecular diagnostics and personalized medicine. Cytojournal. 2014; 11:7. PMC: 4007481. DOI: 10.4103/1742-6413.129187. View

11.

Rekhtman N . Neuroendocrine tumors of the lung: an update. Arch Pathol Lab Med. 2010; 134(11):1628-38. DOI: 10.5858/2009-0583-RAR.1. View

12.

Lin O, Olgac S, Green I, Zakowski M, Klimstra D . Immunohistochemical staining of cytologic smears with MIB-1 helps distinguish low-grade from high-grade neuroendocrine neoplasms. Am J Clin Pathol. 2003; 120(2):209-16. DOI: 10.1309/TGCD-66L3-1DHY-X5HK. View

13.

Commins D, Atkinson R, Burnett M . Review of meningioma histopathology. Neurosurg Focus. 2007; 23(4):E3. DOI: 10.3171/FOC-07/10/E3. View

14.

Gruchy J, Barnes P, Dakin Hache K . CytoLyt® fixation and decalcification pretreatments alter antigenicity in normal tissues compared with standard formalin fixation. Appl Immunohistochem Mol Morphol. 2014; 23(4):297-302. DOI: 10.1097/PAI.0000000000000082. View

15.

Travis W, Brambilla E, Riely G . New pathologic classification of lung cancer: relevance for clinical practice and clinical trials. J Clin Oncol. 2013; 31(8):992-1001. DOI: 10.1200/JCO.2012.46.9270. View

16.

Wagner D, Russell D, Benson J, Schneider A, Hoda R, Bonfiglio T . Cellient™ automated cell block versus traditional cell block preparation: a comparison of morphologic features and immunohistochemical staining. Diagn Cytopathol. 2010; 39(10):730-6. DOI: 10.1002/dc.21457. View

17.

Acs B, Kulka J, Kovacs K, Teleki I, Tokes A, Meczker A . Comparison of 5 Ki-67 antibodies regarding reproducibility and capacity to predict prognosis in breast cancer: does the antibody matter?. Hum Pathol. 2017; 65:31-40. DOI: 10.1016/j.humpath.2017.01.011. View

18.

Howat W, Wilson B . Tissue fixation and the effect of molecular fixatives on downstream staining procedures. Methods. 2014; 70(1):12-9. PMC: 4240801. DOI: 10.1016/j.ymeth.2014.01.022. View

19.

Pelosi G, Rindi G, Travis W, Papotti M . Ki-67 antigen in lung neuroendocrine tumors: unraveling a role in clinical practice. J Thorac Oncol. 2014; 9(3):273-84. DOI: 10.1097/JTO.0000000000000092. View

20.

Gong Y, Sun X, Michael C, Attal S, Williamson B, Bedrossian C . Immunocytochemistry of serous effusion specimens: a comparison of ThinPrep vs cell block. Diagn Cytopathol. 2003; 28(1):1-5. DOI: 10.1002/dc.10219. View